MDB Capital (NASDAQ:MDBH) Posts Earnings Results

MDB Capital (NASDAQ:MDBH) announced its earnings results on Thursday. The company reported ($0.90) EPS for the quarter, FiscalAI reports. The company had revenue of ($2.33) million during the quarter.

Here are the key takeaways from MDB Capital’s conference call:

• Microcap markets remain challenging: Management said small public and private companies are being neglected, and MDB’s planned expansion from one launch every 18 months to three to five launches annually is being deferred. Revenue is expected to remain lumpy as the company prioritizes a smaller number of high-conviction opportunities.
• MDB plans to operate more leanly without dilution: The company is targeting approximately $5 million–$6 million in annual operating expenses, expects portfolio companies to fund themselves as they mature, and said it is not seeking to raise additional capital at the MDB level.
• Public Ventures may generate near-term strategic value: MDB is in discussions with four or five potential partners regarding a partnership or sale of its clearing platform and aims to complete a transaction in the next quarter.
• PatentVest is pivoting toward an AI-enabled patent law firm: MDB plans to spin the business out as an independently financed entity, using AI and an alternative business structure to improve patent-prosecution efficiency and potentially attract legal talent and clients.
• Portfolio catalysts are approaching: eXoZymes is pursuing scalable manufacturing and commercial partnerships, while Paulex Bio is targeting an IPO in the fourth quarter and expects important diabetes-related clinical data in early 2027. Management characterized both assets as having substantial upside, though execution and financing risks remain.

MDB Capital Stock Performance

Shares of NASDAQ:MDBH traded down $0.04 during trading hours on Friday, hitting $2.98. 1,347 shares of the company’s stock traded hands, compared to its average volume of 2,333. MDB Capital has a 52 week low of $2.45 and a 52 week high of $4.80. The company’s fifty day simple moving average is $3.12 and its two-hundred day simple moving average is $3.25. The company has a market cap of $30.69 million, a price-to-earnings ratio of -1.37 and a beta of 1.21.

Institutional Trading of MDB Capital

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in MDB Capital during the second quarter worth approximately $27,000. DRW Securities LLC bought a new position in shares of MDB Capital in the fourth quarter valued at $40,000. Finally, Citadel Advisors LLC bought a new position in shares of MDB Capital in the third quarter valued at $43,000. 0.35% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of MDB Capital in a research report on Thursday, July 2nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, MDB Capital presently has a consensus rating of “Sell”.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business.